EQFILL is the leading collection of Korean monophonic dermal fillers for the face, featuring three distinct products tailored to your specific needs. Enhance facial volume with EQFILL Fine, Deep, and Sub-Q.

EQFILL Dermal Fillers Important Information

EQFILL is the leading collection of Korean monophonic dermal fillers for the face, featuring three distinct products tailored to your specific needs. Enhance facial volume with EQFILL Fine, Deep, and Sub-Q.

Whatever your goals, we have the solutions to help you achieve the results you desire.

INDICATIONS

EQFILL Fine injectable gel is designed for lip augmentation and the correction of perioral wrinkles, as well as improving infraorbital hollowing in adults aged 21 and older.

EQFILL Deep injectable is intended for deep (subcutaneous and/or supraperiosteal) injection to enhance cheek volume, address age-related deficits in the mid-face, and correct moderate to severe facial wrinkles and folds, including nasolabial folds, in adults over 21.

EQFILL Sub-Q injectable gel is suitable for subcutaneous and/or supraperiosteal injection to enhance jawline and nose definition in adults aged 21 and older, particularly for those experiencing moderate to severe loss of jawline definition.

IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS

These products are not recommended for individuals with severe allergies, particularly those with a history of anaphylaxis or multiple severe allergies. Additionally, they should not be used by patients who have a known allergy to Gram-positive bacterial proteins or lidocaine present in these formulations.

WARNINGS

• Avoid injecting into blood vessels. Introducing these products into the vascular system can lead to serious complications such as embolization, vessel occlusion, ischemia, or infarction. When administering soft tissue fillers, exercise caution: after inserting the needle and just before injection, slightly withdraw the plunger to aspirate and confirm that the needle is not intravascular. Inject the product slowly and apply only the necessary amount of pressure. Although rare, serious adverse events related to intravascular injection of facial fillers have been reported, including temporary or permanent vision impairment, blindness, cerebral ischemia or hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. If a patient shows any signs of changes in vision, stroke symptoms, skin blanching, or unusual pain during or shortly after the procedure, immediately discontinue the injection and seek prompt medical attention, potentially involving a specialist.

• Defer product use at sites with active inflammatory processes. This includes areas affected by skin conditions like cysts, pimples, rashes, or hives, until the underlying issue has been addressed and controlled.

PRECAUTIONS

• To reduce the risk of potential complications, these products should only be administered by healthcare professionals who possess a thorough understanding of the relevant anatomy and the specific product(s) intended for use in designated areas. They should also have appropriate training in facial anatomy, vascular structures, safe injection techniques, and the identification and management of potential adverse events, including intravascular complications.

• It is essential to discuss the potential risks associated with soft tissue injections with patients prior to treatment so they are aware of the signs and symptoms of possible complications.

• The safety and effectiveness of these products for treating anatomical regions outside the indicated areas have not been established through controlled clinical studies. The safety of these products in patients with a known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied. The safety of these products during pregnancy and breastfeeding has not been established.

• The safety of EQFILL has been confirmed for patients aged 35 to 65 for cheek augmentation and for patients aged 22 to 80 years. Dermal filler implantation carries an inherent risk of infection; therefore, standard precautions should always be followed. Caution is advised when using dermal fillers in patients undergoing immunosuppressive therapy.

• Patients taking medications that can prolong bleeding, such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin, may experience increased bruising or bleeding at the treatment sites. Patients with skin injuries near the implantation site may be at a higher risk for adverse events.

• If considering laser treatments, chemical peels, or any other procedures that provoke an active dermal response after treatment, or before the skin has fully healed from a prior procedure, there may be a risk of triggering an inflammatory reaction at the injection site.

ADVERSE EVENTS

The most frequently reported side effects of EQFILL dermal fillers include redness, swelling, pain, tenderness, firmness, lumps or bumps, bruising, discoloration, and itching or dryness. Most of these effects were mild to moderate in severity.

© 2025 Haim Aesthetics.  All rights reserved.

All trademarks are the property of their respective owners.